Navigation Links
PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
Date:12/17/2007

- Company Initiates Phase1b/2 Clinical Trial in Breast Cancer -

SAN ANTONIO and SOUTH PLAINFIELD, N.J., Dec. 17 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms announced the presentation of preclinical and Phase 1 data regarding PTC299, its novel, internally discovered, vascular endothelial growth factor (VEGF) inhibitor. PTC299 is an orally bioavailable investigational drug which is designed to inhibit the production of VEGF in tumors, acting upstream of current anti-angiogenic agents that function at the site of the VEGF receptor. The preclinical and clinical data presented today formed the basis for the recent initiation of a Phase 1b/2 clinical trial of PTC299 in patients with advanced breast cancer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

"We are pleased to present these preclinical data on PTC299, which show drug activity in multiple preclinical models of human cancer, including breast cancer," said Langdon Miller, M.D., Chief Medical Officer of PTC Therapeutics, Inc. "Based on the safety profile and pharmacokinetic results from our Phase 1a studies, we are excited to have initiated a Phase 1b/2 trial of PTC299 in patients with advanced breast cancer. Our hope is that PTC299 will offer an active, well-tolerated, and convenient oral therapy for patients with breast cancer and other tumor types."

The data were detailed in a poster presentation at the San Antonio Breast Cancer Symposium entitled, "Preclinical Efficacy in Breast Cancer Xenografts and Phase 1 Results of PTC299, a Novel VEGF Expression Inhibitor," (Poster Number 6082).

In the preclinical studies, PTC299 was administered to mice harboring established human breast tumor xenografts. In these studies,
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/k2h2k9/investigation ) ... on China,s Raloxifene Market, 2010-2019" report to their ... million people suffer from osteoporosis in the world. Among ... , 50% have low bone mass or osteoporosis ... and above. Raloxifene (raloxifene hydrochloride), a non-hormone drug ...
(Date:9/3/2015)... , Sept. 3, 2015 ... proprietary Modoo Fetus Monitoring Patch, a wearable medical device ... deliver fetal movement data, providing safety guidance for pregnant ... The device, which measures 4 centimeters ... and weighs a little more than an Apple earphone ...
(Date:9/3/2015)... FRAMINGHAM, Mass. , Sept. 3, 2015 ... a leading innovator of less invasive, miniaturized circulatory support ... failure, today announced that its President and Chief Executive ... at the 2015 Wells Fargo Healthcare Conference at 8:50 ... being held Sept. 9-10, 2015 at The Hyatt Regency, ...
Breaking Medicine Technology:Investigation Report on China's Raloxifene Market, 2015-2019 2Modoo to Debut at Kickstarter: First Device on the Market that Enables Continuous Monitoring of Fetal Heart Rate and Fetal Movement 2HeartWare Presentation At The 2015 Wells Fargo Healthcare Conference To Be Webcast 2
... PRINCETON, N.J., Jan. 10, 2011 CoreLab Partners, ... between RadPharm, Inc and Medifacts International, has launched a ... "We are pleased to announce the release of ... the drug development continuum by offering sponsors advanced technologies ...
... Jan 10, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited ... and marketer of medical devices worldwide, today announced updates ... pipeline for domestic and international markets in 2011. ... of ten products, meeting new product development goals outlined ...
Cached Medicine Technology:CoreLab Partners Launches Advanced Imaging Application 2CoreLab Partners Launches Advanced Imaging Application 3Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline 2Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline 3Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline 4
(Date:9/3/2015)... ... September 03, 2015 , ... Dr. Robert Winchell has been appointed director of ... Care at NewYork-Presbyterian/Weill Cornell Medical Center, effective July 27. He will serve on the ... in care for the critically injured and the development, design and operations of trauma ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... Global ... announced that it will be spotlighting its award-winning print and artwork inspection solutions, ... team September 16 and 17 at the Olympia London, booth #F33 , Be the ...
(Date:9/3/2015)... ... September 03, 2015 , ... Atlantic Information Services, ... “Proven Pharmacy Benefit Strategies for a Rapidly Changing Marketplace.” In this Sept. 16 ... Milliman, will discuss how plan sponsors are adopting bold, innovative strategies to control ...
(Date:9/3/2015)... TEXAS (PRWEB) , ... September 03, 2015 , ... ... the Lone Survivor Foundation with a champion AKC Black Lab Puppy. Celebrate Fall 2015 ... canine companion, for friends and family to enjoy Thanksgiving and Christmas with an extra ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ProScrub is ... create back & forth, flicker, repeat, and custom speed effects without the use of ... the speed of effect. ProScrub tools are perfect complements to energetic video productions. ...
Breaking Medicine News(10 mins):Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Speakers for Upcoming AIS Virtual Conference on Pharmacy Benefit Strategies Include Executives from CVS Health, Express Scripts 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2
... June 6 (HealthDay News) -- Men who have type 2 ... from a regular exercise regimen, a new study has found. ... boost survival rates for men with both conditions, researchers found. ... which commonly occurs in people with diabetes and high blood ...
... A new poll by the Harvard School of Public Health ... the health care reform legislation enacted in 2006, 21% oppose ... heard or read about the law. The percentage of residents ... Support for the law varied by party affiliation, with 77% ...
... Hull have discovered a way to load up nanoparticles ... more effective form of photodynamic therapy (PDT) for treating ... light, cause irreparable damage to cells by creating toxic ... works with individual light-sensitive molecules but the new ...
... CHICAGO As the world marks the 30-year anniversary of ... a new challenge for people with the incurable disease. ... higher rate of cancers not usually associated with HIV. ... and neck, liver, kidney, and anal cancers, among others. ...
... A new targeted therapy for prostate cancer halts tumor ... resistant to hormone therapy, a new study finds. The ... 93rd Annual Meeting in Boston. "This targeted therapy ... lives of men with advanced, hormone-refractory prostate cancer," said ...
... Amanda Gardner HealthDay Reporter , SATURDAY, June 4 ... cancer drug, Avastin, may benefit both early stage ovarian cancer ... both studies, presented Saturday at the annual meeting of the ... added to standard chemotherapy. But the high cost ...
Cached Medicine News:Health News:Exercise Helps Men Battling Diabetes and Sleep Apnea 2Health News:Support for Massachusetts landmark health reform law rises in 2011 2Health News:Support for Massachusetts landmark health reform law rises in 2011 3Health News:Research creates nanoparticles perfectly formed to tackle cancer 2Health News:Many of those living with HIV face a new life-threatening challenge: cancer 2Health News:Many of those living with HIV face a new life-threatening challenge: cancer 3Health News:Targeted cancer therapy kills prostate tumor cells 2Health News:Cancer Drug Avastin Makes Inroads Against Ovarian Tumors 2Health News:Cancer Drug Avastin Makes Inroads Against Ovarian Tumors 3
KIMBERLY-CLARK BALLARD Neonatal and Pediatric TRACH CARE Y features lavage/irrigation port and locking thumb port. Multiple French sizes and packaging configurations. Gamma sterilized....
... tubes include an obturator, ... disconnect wedge, cleaning brush, ... inner cannulae., ,Uncuffed ... Velcro® trach tube holder, ...
... patients with obstructive sleep apnea necessitating tracheotomy, ... support. Also indicated where airway access for ... ,Another excellent choice for a sleep ... tube series. Available with a low profile ...
Fenestrations allow your patients to vocalize when cuff is deflated...
Medicine Products: